Drug General Information (ID: DDI0YROTDM)
Drug Name			Alemtuzumab		Drug Info		Lenalidomide		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Antineoplastics

Mechanism of Alemtuzumab-Lenalidomide Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Alemtuzumab				Lenalidomide
Mechanism 1		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Alemtuzumab and Lenalidomide
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Alemtuzumab				Lenalidomide
Mechanism 2		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 2
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Alemtuzumab and Lenalidomide

Recommended Action
Management		Caution is advised if alemtuzumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. The manufacturer recommends that single doses of alemtuzumab not exceed 30 mg and cumulative weekly doses not exceed 90 mg, since higher dosages are associated with an increased incidence of pancytopenia. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.

References
1	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.